P136 | CLINICAL BENEFITS OF EARLY USE OF AVATROMBOPAG AS FIRST-LINE TPO-RA IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC IMMUNE THROMBOCYTOPENIA: THE EARLIER YOU START, THE LESS YOU NEED? A SINGLE-CENTER EXPERIENCE.
Introduction: Immune thrombocytopenia (ITP) is a rare autoimmune disorder caused by immune-mediated platelet destruction. After initial treatment with corticosteroids and/or immunoglobulins, second-line therapies for chronic or refractory ITP include thrombopoietin receptor agonists (TPO-RAs) such...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Ferrata Storti Foundation
2025-09-01
|
| Collection: | Haematologica |
| Accès en ligne: | https://haematologica.org/article/view/12433 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|